NGeneBio Co

NGeneBio Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is -1.61 %. In the previous year, CapEx to Operating Cash Flow Ratio was -1.92 % — a change of -16.32% (higher).

CapEx/OCF

-1.61 %

YoY

-16.32%

Last updated:

CapEx to Operating Cash Flow Ratio of NGeneBio Co is 2025 -1.61 % . CapEx to Operating Cash Flow Ratio of NGeneBio Co was 2024 -1.92 % . It decreases by -16.32% higher compared to the previous year.

The NGeneBio Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-28.07 KRW
Jan 1, 2019
-139.64 KRW
Jan 1, 2020
-9.84 KRW
Jan 1, 2021
-38.65 KRW
Jan 1, 2022
-15.66 KRW
Jan 1, 2023
-9.03 KRW
Jan 1, 2024
-1.92 KRW
Jan 1, 2025
-1.61 KRW
The NGeneBio Co CapEx/OCF history
YEARCapEx/OCFYoY
-1.61 %-16.32%
-1.92 %-78.73%
-9.03 %-42.32%
-15.66 %-59.48%
-38.65 %+292.97%
-9.84 %-92.96%
-139.64 %+397.54%
-28.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

CapEx to Operating Cash Flow Ratio of NGeneBio Co is -1.61 % in 2025.

CapEx to Operating Cash Flow Ratio of NGeneBio Co changed from -1.92 % to -1.61 %, representing a -16.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NGeneBio Co

All Key Metrics — NGeneBio Co